Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Teva Pharmaceutical Industries (TEVA) has become a focus ...

Greenlight Capital, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Greenlight Capital’s investment strategy focuses on ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development of a drug for vitiligo. The deal centers around TEV-‘408, an anti-IL-15 ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable healthcare stocks to buy now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on December 24 that S&P ...

Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their ...

Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their ...

Pfizer (PFE) posted Q3 revenue of $16.65B down 5.9% as COVID products declined sharply. Paxlovid dropped 55% and Comirnaty fell 20%. Teva (TEVA) delivered its 11th consecutive quarter of growth with ...

Teva Pharmaceutical Industries is launching its first global innovation platform, challenging startups to submit novel strategies to tackle seven pervasive industry hurdles that run the gamut from ...

Teva's generic Saxenda is the first generic GLP-1 indicated for weight loss. Richardsen added, “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva ...

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report. Got a confidential news tip? We want to hear from you. Sign up for free ...

BD9 blocks both TSLP and IL-13, two major drivers of TH2 inflammation. Biolojic to receive milestone payments tied to BD9 development progress. Special Access: Get Market Moving News Up to 15 Minutes ...